Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Sarcoma, Myeloid 1Leukemia, Myeloid, Acute 1

Interventions

Specimen Handling 39Magnetic Resonance Spectroscopy 33Cyclophosphamide 30Doxorubicin 24Biopsy 24pembrolizumab 22Temozolomide 22Radiotherapy 20Radiation 19X-Rays 18Nivolumab 15Vincristine 13Irinotecan 13fludarabine 12Phantoms, Imaging 12Ifosfamide 12Gemcitabine 12atezolizumab 11cabozantinib 10Ipilimumab 9Bevacizumab 9liposomal doxorubicin 8Surgical Procedures, Operative 8Paclitaxel 8Immunoglobulin G 8Etoposide 8Dactinomycin 7Carboplatin 7palbociclib 6olaparib 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leyk × Sarcoma × 90 days × Clear all
NCT01371981 2026-06-02

Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

National Cancer Institute (NCI)

Phase 3 Completed
1,645 enrolled 32 charts
Other hematologic neoplasmSarcoma

Leukemia, Myeloid, Acute, Sarcoma, Myeloid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡